Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety

Ashley Taylor; Nigel Irwin; Aine McKillop; Steven Patterson; Peter  Flatt; Victor Gault

doi:10.1677/JOE-10-0085

Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety

Ashley Taylor, Nigel Irwin, Aine McKillop, Steven Patterson, Peter Flatt, Victor Gault

Biological and Biomedical Sciences

Research output: Contribution to journal › Article

Abstract

Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.

Original language	English
Pages (from-to)	87-93
Number of pages	7
Journal	Journal of Endocrinology
Volume	207
Issue number	1
DOIs	https://doi.org/10.1677/JOE-10-0085
Publication status	Published - Oct 2010

Keywords

xenin peptide
insulin secretion
type 2 diabetes
glucose homoeostasis

Documents and Links

10.1677/JOE-10-0085

Fingerprint Dive into the research topics of 'Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety'. Together they form a unique fingerprint.

Cite this

@article{3887ebafcb334720adc7ada556bd141f,

title = "Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety",

abstract = "Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.",

keywords = "xenin peptide, insulin secretion, type 2 diabetes, glucose homoeostasis",

author = "Ashley Taylor and Nigel Irwin and Aine McKillop and Steven Patterson and Peter Flatt and Victor Gault",

year = "2010",

month = oct,

doi = "10.1677/JOE-10-0085",

language = "English",

volume = "207",

pages = "87--93",

journal = "Journal of Endocrinology",

issn = "0022-0795",

publisher = "BioScientifica",

number = "1",

}

TY - JOUR

T1 - Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety

AU - Taylor, Ashley

AU - Irwin, Nigel

AU - McKillop, Aine

AU - Patterson, Steven

AU - Flatt, Peter

AU - Gault, Victor

PY - 2010/10

Y1 - 2010/10

N2 - Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.

AB - Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.

KW - xenin peptide

KW - insulin secretion

KW - type 2 diabetes

KW - glucose homoeostasis

U2 - 10.1677/JOE-10-0085

DO - 10.1677/JOE-10-0085

M3 - Article

VL - 207

SP - 87

EP - 93

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 1

ER -